Explores the potential of psychedelics as medicine and the intersections of politics, science, and psychedelics

• Explores the tumultuous background of psychedelic study, the efforts to restore psychedelic therapies, and the links between psychiatric drugs and mental illness

• Offers non-technical summaries of the very most latest, double-blind, placebo-controlled research with MDMA, psilocybin, LSD, and ayahuasca

• Includes the work of Rick Doblin, Stanislav Grof, Wayne Fadiman, Julie Holland, about Psychedelic Medication: The Recovery Power of LSD, MDMA, Psilocybin, and Ayahuasca Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker

Embracing the revival of psychedelic research as well as the discovery of new therapeutic uses, clinical psychologist Dr. Richard Louis Miller discusses what’s taking place today in psychedelic medicine–and exactly what will happen in the future–with best experts and thinkers with this field, including Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker.

Dr. Miller and his contributors cover the tumultuous history of early psychedelic research brought to a halt 50 years ago from the U.S. federal government aswell as offering non-technical summaries of the most recent research with MDMA, psilocybin, LSD, and ayahuasca. They explore the biochemistry of awareness and the use of psychedelics for self-discovery and healing. They discuss the use of psilocybin for releasing fear in the terminally sick and the prospect of MDMA-assisted psychotherapy in the treating PTSD. They examine Dr. Charles Grob’s research in the indigenous make use of and healing properties of ayahuasca and Dr. Gabor Mate’s try to transportation this plant medication to a clinical setting by using Canada’s Division of National Health.

Dr. Miller and his contributors explore the ongoing attempts to revive psychedelic therapies to the health field, the growing risk of overmedication by the pharmaceutical market, as well as the links between psychiatric medications and mental illness. They also discuss the newly shifting political weather and the force for new research, offering expect an end to the War on Medicines and a potential renaissance of study into psychedelic medicines all over the world.